# Beyond the Blunt Instruments

### The case for targeted PRRT2 therapies

*An Alliance Perspective — a personal essay by PRRT2.org, who lives with PRRT2 · May 28, 2026*

{% hint style="success" %}
**🧭 PRRT2.org Perspective**

*PRRT2.org's own perspective — our synthesis and lived experience, offered alongside the established science, not as established medical fact. Nothing here is medical advice, and nothing here is a reason to start, stop, or change a medication on your own. Those decisions belong with your specialist.*
{% endhint %}

When you navigate a PRRT2 diagnosis — as an adult who is finally being named, or as a family caring for a child — you hit a frustrating reality fast: we manage this condition almost entirely with **hand-me-down medications.**

For decades the full reach of PRRT2 was poorly understood, and countless adults paid for it. People spent years — sometimes whole lives — labeled with something else: atypical seizures called ordinary epilepsy, paroxysmal movements written off as a tic disorder or as something psychological, migraines and dystonic episodes treated in isolation by clinicians who never saw the thread connecting them. When the genetic diagnosis finally arrives, it comes with a second hard truth: the treatments are decades behind the science that named the gene.

<figure><img src="/files/MfmZTwmkU3zWjFcOJVAj" alt=""><figcaption></figcaption></figure>

## A spectrum, one mechanism, no dedicated drug

Whether the problem shows up as infantile seizures, as kinesigenic episodes (PKD), as exertional ones (PED), or — as in my case — as dystonia and dysphonia that arrived young and generalized over time, the underlying mechanism is shared: PRRT2 normally helps keep neural circuits stable, and without enough of it, those circuits tip too easily into misfiring. (See [The Sodium Channel Connection](https://www.prrt2.org/prrt2-gene-overview/sodium-channel-connection).)

And yet there is **no drug designed for PRRT2.** The mainstay is the broad-spectrum sodium-channel anticonvulsant — carbamazepine and its relatives — borrowed from epilepsy. Other repurposed agents, including anticholinergics like trihexyphenidyl (Artane), get reached for when dystonic features are prominent, as they are in dystonia more generally. None of these was built for this gene. They are what was already on the shelf.

The clinical literature tends to celebrate these drugs for one thing: they stop episodes. And often they do. But "the episodes stopped" is not the same sentence as "the person is well."

## The cost of a blunt instrument

Carbamazepine is, mechanically, a **blunt instrument.** It blocks voltage-gated sodium channels indiscriminately — not only the overactive circuits driving the episodes, but the healthy ones underneath that were doing their jobs. The misfiring quiets down, and so does a great deal that was never the problem.

For some people, that trade is worth making — episodes drop dramatically, life becomes navigable, and the cognitive cost is something they can absorb. That's the version the literature describes, and for those patients it's a real and meaningful improvement.

For others, the picture is different. Some people get the cost without the full payoff — the fog, the slowing, the dulled thinking, the side effects — and the episodes don't fully stop. Some carry the cognitive tax indefinitely with only partial control of what the drug was supposed to control. I'm one of them. On carbamazepine I felt spacey and underwater; life slowed to a crawl; my thinking dulled to the point that I could barely drive, on top of skin reactions. And the storms kept coming.

A clinical trial would have recorded a "partial response," maybe a "successful reduction in dyskinesia," in the patients who match the textbook picture. It would not have recorded the rest of us — the cognitive cost without the full payoff, the cure that brought its own disability without delivering on its promise. There is a name for the first half of that bargain. There isn't really one for the second.

That gap — between what the trials measure and what the drug actually costs the people taking it — is the heart of the problem. **Stopping the misfiring is only half of medicine. The other half is whether you can still live the way you want to. And for some of us, even that half isn't reliably bought.**

## My picture, and a different bargain

My dystonia and dysphonia didn't come and go — they came young and they generalized, the way early-onset dystonia so often does, taking more of the body with it over the years. The blunt drugs built for other conditions didn't just fail to fully control the storms; for me they made it worse on both sides — more resistance, more side effects, less of me left over.

So with my doctors, I had to make a different bargain. Not total suppression — that was never on offer for me anyway — but *livable*. Lighter, individualized, supervised — accepting more breakthrough in exchange for keeping my mind and my function.

I won't publish that regimen as a recipe, and I want to be honest about why. What balances one person can harm another. Some of the adjuncts people reach for — benzodiazepines especially — carry real dependence and withdrawal risks, and getting them wrong can make seizures and dystonia worse, not better. A one-size protocol is exactly the kind of thinking that failed us to begin with.

The point was never my specific cocktail. It's that I have to improvise one at all. That improvising — done quietly by patients and good doctors everywhere, because nothing was ever designed for this gene — isn't a solution. It's the clearest evidence there is of how far behind the treatments are.

## Blunt isn't the only tool — and shouldn't be the destination

Let me be clear about one thing, because I don't want anyone to read this as "avoid treatment." For many people, these medications are genuinely life-changing, and intolerance to one blunt tool does not close the door. There are **more selective** options worth raising with a specialist. **Lacosamide**, for instance, acts on the *slow* inactivation of sodium channels — it preferentially quiets the rapid burst-firing that drives episodes while leaving ordinary firing more intact, which can mean control with less of the global fog. **Eslicarbazepine** and **lamotrigine** are other, cleaner-profile members of the broad family; **acetazolamide**, which isn't a sodium-channel drug at all, sometimes helps the exertional and atypical presentations. (See [Medications](https://www.prrt2.org/treatments-and-management/medications) — which, if any, fits a given person is entirely a specialist's call.)

But notice what even the good news is: precision *within a borrowed class.* A more selective anticonvulsant is still an anticonvulsant designed for something else, fitted to us as best it can be. That is real progress for a patient choosing today. It is not the destination.

## Why we advocate

This is exactly why the PRRT2 Gene Alliance exists. We do not accept the current standard of care as the finish line.

We want the scientific and pharmaceutical communities to recognize that stopping a seizure or a dyskinetic episode is only the beginning of the job. The goal is a therapy that addresses the **PRRT2 mechanism itself** — the shared root beneath the whole spectrum — so that neither a child nor an adult is ever forced to choose between the physical storms and the cognitive fog. (See [Future Therapeutics](https://www.prrt2.org/research/future-therapeutics) for where that science might lead, told honestly.)

Until that therapy exists, the least we can do is name the gap out loud — and make sure no one believes that "the episodes stopped" was ever the whole of what they were owed.

***

*Have you faced this trade-off between control and clarity? Your experience is part of the case we're making. Share it through our community — see* [*Links & Support*](https://www.prrt2.org/resources/links-and-support) *— or read others' on* [*Patient Stories*](https://www.prrt2.org/living-with-prrt2/patient-stories)*.*

## Continue reading

* [How Treatment Works for PRRT2](https://www.prrt2.org/treatments-and-management/how-treatment-works) — the current landscape
* [Carbamazepine](https://www.prrt2.org/treatments-and-management/medications/carbamazepine) — the established first-line drug, in full
* [Future Therapeutics](https://www.prrt2.org/research/future-therapeutics) — the case for targeted treatment


---

# Agent Instructions: Querying This Documentation

If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.

Perform an HTTP GET request on the current page URL with the `ask` query parameter:

```
GET https://www.prrt2.org/perspectives/articles/beyond-blunt-instruments.md?ask=<question>
```

The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.